# Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

> **NCT02263898** · PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** Raf kinase inhibitor LGX818
- **DRUG:** binimetinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02263898
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** closed without enrollment
- **Last updated:** 2020-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02263898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02263898, "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02263898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*